kentucky semaglutide intestinal paralysis law office glp-1 in New clinical trial data from Eli Lilly shows As GLP-1 drugs continue to

Ongoing Medical Supervision and Support Long-term use of tirzepatide requires continuous medical supervision

Professional support from licensed healthcare providers

Published on April 6th, 2026

The attorneys general identified the following concerns including: Counterfeit semaglutide imported from China, Turkey and India and repackaged as FDA-approved products Online sellers promoting research-only peptides while providing instructions for human injection Consumers mixing raw powders at home, leading to overdoses, contamination and serious adverse events Compounding pharmacies operating around legal boundaries, including insanitary conditions and high-impurity formulations Risks of hospitalization tied to dosing errors and adulterated ingredients The attorneys general asked the FDA and the Department of Homeland Security to take joint action to intercept illegal imports and protect patient safety

As of April 2026, no oral tirzepatide formulation tablet, buccal, sublingual, or otherwise is FDA-approved in the United States